Contribute Try STAT+ Today

PhRMA, the pharmaceutical industry trade group, took in nearly $527 million in revenue last year, a $68 million increase from 2018 that came as the industry faced unprecedented opposition in Washington. 

The new revenue figure, made public late this year in PhRMA’s federal tax disclosures, highlights the group’s diverse efforts to influence Washington in a year when both the White House and newly empowered Democrats in the House of Representatives were intent on capping drug prices. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The reason that PhRMA is so ineffective is because so many people get paid too much. They’re too cautious, too afraid to lose their cushy jobs, too paralyzed by fear they’ll get fired if they fail. There is not a single person there other than the CEO who would get a similar salary at another association or agency. I’m shocked the Pharma executives put up with that level of spending,

Comments are closed.